Vertex Pharmaceuticals
UK's MHRA Approves Vertex's Cystic Fibrosis Drug Alyftrek
The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.
CHMP Recommends Vertex's Kaftrio, Kalydeco Combo for Additional Cystic Fibrosis Patients
The committee supports approving the CFTR modulator for patients 2 years and older with at least one non-class I CFTR gene mutation.
JP Morgan Healthcare Conference, Day 1: Vertex, Bristol Myers Squibb, Gilead, Sarepta, and More
On the first day, Vertex discussed regulatory plans for a kidney disease drug, BMS and Merck talked about pipeline diversification, and Gilead offered updates on anito-cel.
Payors, Pharma Engage Alternative Payment Models Amid High Gene Therapy Cost, Efficacy Unknowns
Premium
Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.
Vertex Grabs Rights to Orum's Targeted Protein Degradation Technology
The deal, valued at more than $325 million, gives Vertex the right to use Orum's technology to develop new targeted conditioning agents for its gene therapies.